康哲药业(00867.HK)今日盘中大涨8.16%,报收8.24港元,成交活跃。消息面上,该公司旗下一款白癜风创新药物芦可替尼乳膏的新药上市许可申请(NDA)已于9月24日获国家药监局受理。
数据显示,芦可替尼乳膏在中国真实世界研究中取得了积极疗效,治疗组非节段型白癜风患者皮损减退49.5%,远超14.1%的目标值。芦可替尼乳膏是针对目前无同类上市产品的全新治疗方式,如果获批上市,将有望填补该领域的空白。
据估算,芦可替尼乳膏的潜在目标人群庞大。中国约有1400万白癜风患者,其中约85%为非节段型,而东南亚地区患者数也超650万。分析人士预期,如果这一创新药物成功上市,将有望获得较大市场机会。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.